Person:
ÇAM, MUHAMMET EMİN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ÇAM

First Name

MUHAMMET EMİN

Name

Filters

2021 - 20222
Reset filters

Settings

Author: GÜNDÜZ, OĞUZHAN × Subject: Alzheimer's disease ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    A Comparison Study of Fiber Diameter's Effect on Characteristic Features of Donepezil/Curcumin-Loaded Polycaprolactone/Polylactic Acid Nanofibers
    (2022-05-01) EKENTOK ATICI, CEYDA; GÜNDÜZ, OĞUZHAN; ÇAM, MUHAMMET EMİN; TATAR, ESRA; YAVUZ, AYŞE NUR; Aydin S., Kabaoglu I., Guler E., Topal F., YAVUZ A. N., EKENTOK ATICI C., TATAR E., Gurbuz F., GÜNDÜZ O., ÇAM M. E.
    Nanofibers (NFs) offer an alternative option for the treatment of Alzheimer\"s disease (AD) by addressing unmet clinical problems. In this study, anti-AD drugs, donepezil (DO) and curcumin (CUR), are loaded in polylactic acid/polycaprolactone NFs. The effect of fiber diameter on drug release behavior is mainly observed, and the successful loading of DO and CUR to NFs is demonstrated. The tensile strength of DO/CUR-loaded NFs (DNFs) with lower fiber diameter is found to be higher. The working temperature is increased by the decrease of glass transition temperature and increase of the melting temperature after loading drugs. Furthermore, the increase in the percentage of swelling and decrease in the degradation rate for NFs are observed due to the increase of fiber diameter. Encapsulation efficiency and burst release percentages for DNFs are augmented by the increase of fiber diameter. Nevertheless, DNFs exhibit a sustained drug release manner over 2 weeks. NFs do not demonstrate a toxic effect on L929 (mouse fibroblast) cells, and additionally, they promote cell proliferation. Considering all these results, it is proven that the fiber diameter affects all characteristic features of NFs, and DNFs lead to a new and promising drug delivery system for the treatment of AD.
  • No Thumbnail Available
    PublicationMetadata only
    Electrically controlled drug release of donepezil and BiFeO3 magnetic nanoparticle-loaded PVA microbubbles/nanoparticles for the treatment of Alzheimer's disease
    (Editions de Sante, 2021) SAYIN, FATİH SERDAR; Cesur S., Cam M.E., Sayin F.S., Gunduz O.
    Nanocarriers are used to deliver bioactive substances in the treatment of neurodegenerative diseases such as Alzheimer's disease (AD). These nanocarriers have shown many benefits over traditional treatments due to their properties such as efficient distribution and controlled release of bioactive material to the brain and loading of various drugs simultaneously. In this study, polyvinyl alcohol (PVA), PVA/bismuth ferrite (BiFeO3), and PVA/BiFeO3/donepezil hydrochloride (DO) monodisperse polymeric nanoparticles were manufactured with bursting microbubbles by a T-junction device. Here, BiFeO3 nanoparticles were synthesized by the co-precipitation method, and these magnetic nanoparticles and DO were loaded in PVA nanoparticles. Nanoparticles had a smooth and monodisperse structure according to SEM images. Also, the diameters of PVA, PVA/BiFeO3, and PVA/BiFeO3/DO nanoparticles were 148 ± 15 nm, 159 ± 21 nm, and 164 ± 12 nm, respectively. It was confirmed by X-ray diffraction and infrared spectroscopy that BiFeO3 magnetic nanoparticles and DO were successfully loaded into nanoparticles produced with PVA. There was no cytotoxic effect on healthy L929 cells for all nanoparticle samples. A systematic electrical circuit has been established to investigate the electrically controlled release behaviour of PVA/BiFeO3/DO nanoparticles at different voltages (0 V, −1.0 V, −0.5 V, +0.5 V, +1.0 V), different currents (−50 μA, −100 μA, −200 μA, and −300 μA), and 200 rpm. To apply electric stimulus increased the release except for +1.0 V and the release of DO increased at more negative voltages with a total release of 68.9% of DO after 15 stimulus with −1.0 V. Higher R2 values were obtained with the Higuchi model for almost all conditions and DO was released from nanoparticles through the non-Fickian diffusion mechanism (0.45 < n < 1). The possibility of affecting the release of DO by modifying the current and voltage in the presence of BiFeO3 leads to an immensely controllable and delicately tunable drug release for AD treatment. © 2021